• Lab Express (Phoenix, Arizona) said it has introduced a new at-home colon cancer screening kit. The new Immunoassay Colorectal Cancer Screening (iFOBT) promises results in 7-10 days. Lab Express says iFOBT eliminates false positives and false negatives to offer a more accurate result. Importantly, iFOBT will help more people that shy away from colonoscopies by providing a viable alternative. Although colorectal cancer is one of the deadliest forms of cancer, if caught early it can be cured. The five-year survivability rate for colorectal cancer is 64%, far less than any other cancer that is routinely screened. iFOBT uses sensitive chemical indicators to detect blood traces that are not visible to the naked eye, resulting in increased detection of the disease.

• Medicsight (London), a subsidiary of MGT Capital Investments, reported the submission of a 510(k) pre-market approval notification to the FDA for clearance to market its ColonCAD image analysis software throughout the U.S. Colon CAD technology represents a breakthrough in radiology, providing a tool which can assist radiologists in the detection of colonic lesions. If detected early, colon cancer is often treatable, making Medicsight's Colon CAD technology attractive to both patients and healthcare systems alike.

• Riverain Medical (Dayton, Ohio) said that two of the company's products, the OnGuard chest X-ray CAD system and the SoftView enhanced chest Imaging technology, have been awarded CE marks and Canadian device licenses. Riverain's OnGuard works in conjunction with the reading of standard digital chest X-rays to quickly and comprehensively identify solitary pulmonary nodules that may be early-stage lung cancer. The SoftView technology creates an enhanced soft tissue image of the chest by suppressing bone on a standard chest X-ray. SoftView increases image clarity to help radiologists better detect and diagnose medical conditions such as pulmonary nodules, pneumothoraces and improperly placed lines and tubes.